Navigation Links
SemBioSys begins phase I/II trial of insulin produced in plant seeds
Date:12/3/2008

TSX symbol: SBS

CALGARY, Dec. 3 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing protein pharmaceuticals in crop plants, today announced that it has initiated a phase I/II clinical trial of its plant-produced insulin with the first injection of its drug in humans. The trial, taking place in the United Kingdom (UK), will include up to 30 healthy volunteers in a three-arm study (SBS-1000 insulin and two commercial standards) to demonstrate the bioequivalence of safflower-produced insulin to comparator insulin products. Full results are expected to be available during the first half of 2009.

"We have commenced the planned phase I/II clinical trial with plant-made insulin. This is the largest volume biopharmaceutical ever produced in plants," stated Bruce Given, M.D., acting chief medical officer at SemBioSys. "This sophisticated trial is designed to show bioequivalence with respect to insulin concentrations as well as insulin action on blood glucose. Bioequivalence is being measured by comparing SBS-1000 to commercially available insulin currently used to treat diabetes."

"The initiation of the phase I/II clinical trial for plant-produced insulin is a major milestone for SemBioSys. The trial is the first in which plant-produced insulin has been injected into humans and supports the exciting potential for the establishment of plant-produced drugs in the pharmaceutical sector," said Andrew Baum, president and chief executive officer of SemBioSys. "This trial verifies the viability of plant made insulin and defines the regulatory path for plant-made biopharmaceuticals. This trial also represents significant risk reduction for potential large pharmaceutical partners for our insulin and Apo AI Milano programs."

SemBioSys prepared the clinical material in its Current Good Manufacturing Practice (cGMP) compliant manufacturing plant, which underwent a successful cGMP inspection
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
2. SemBioSys announces second quarter 2008 financial and operational results
3. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
4. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
5. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
6. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
7. SemBioSys announces first quarter 2008 financial and operational results
8. SemBioSys receives milestone payments from AVAC Ltd.
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys announces 2007 financial and operational results
11. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... spotlight on the,ever-growing field of life sciences, Larta Institute,s ... in the midst of the dark backdrop of the,current ... to,focus on brilliant entrepreneurs in the life sciences, even ... years, through good,economic times and bad, the passion and ...
... 14 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced ... & Renshaw 5th Annual Global Healthcare Conference to be ... in Monte Carlo, Monaco.,Jeffrey B. Davis, CEO of Access ... 3:10 pm local time, 9:10 am Eastern time and ...
... May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... has,received a letter of approval from the ... for its Clinical Trial Application (CTA),to begin ... administration of,REOLYSIN(R) in combination with paclitaxel and ...
Cached Biology Technology:Betting on Change - The Venture Forum in 2008 2Betting on Change - The Venture Forum in 2008 3Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ... condition and the best ways to treat it. ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... New knowledge points to the fact that a genetically ... skin barrier, plays a decisive role in the origin ... 3000 school-children scientists of the Helmholtz Zentrum Mnchen and ... the German population carry variations of the filaggrin gene, ...
... (MS), neuroradiologists and neurologists of the University hospitals of ... tissue damage, most of which had remained unrecognized up ... medium, Gadofluorine M, in magnetic resonance imaging. The scientists ... the renowned medical journal Brain . ...
... , Now that Olympia is approaching, the Chinese authorities ... large cities with different measures. For example, the car ... ordered not to use 70 percent of all company ... even or odd days - in accordance with their ...
Cached Biology News:When our protective armor shows weakness 2Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2GKSS membranes reduce air pollution in Beijing 2
... host strains are K-12 derivatives that have ... and glutathione reductase (gor) genes, which greatly ... Studies have shown that expression in Origami(DE3) ... another host even though overall expression levels ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Kit, 1 kit. Convenient way ... Conjugations are carried out under mild ... Dyes are packaged in premeasured amounts ... Category: Blotting & Labeling & Detection, ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: